
Is an innovative screening, diagnosis and monitoring tool for a
COMPLETE
LIVER EVALUATION
and primary liver cancer prevention

Fibronostics Secures Financing,
announces new CEO

LIVERFASt™
for NAFLD, NASH,
HCV, HBV, Cirrhosis.

Help quantify and monitor liver damage in subjects with metabolic risk and fatty liver as well with viral hepatitis.

Fibronostics listed in the top 300
promising AI-driven companies
in life science
